Strategic CDMO Waisman Biomanufacturing is a cGMP contract development and manufacturing organization with a track record of over 320 clinical grade products and a focus on timely, cost-effective production of biotherapeutics for clinical trials. Potential sales angle: position WB as a reliable partner for early-stage biotech firms needing scalable clinical manufacturing and IND support.

Broad Modality Expertise Experience spans gene therapies, cell therapies, vaccines, and recombinant proteins, including plasmid DNA, MSCs, hESCs, adenoviral, lentiviral, and AAV vectors. Potential sales angle: target startups and sponsors developing diverse modalities that require integrated manufacturing and QA/CMC support under one roof.

IND Readiness WB provides full IND support with QA audited batch records, CMC services, and access to a Type V Facility Master File, enabling smoother regulatory submission. Potential sales angle: offer end-to-end regulatory and manufacturing packages to accelerate clinical trial timelines for customers.

Strategic Partnerships Recent collaborations with RoosterBio, Stratatechcorp, GigaGen, and Heat Biologics highlight WB’s ability to form ecosystem partnerships to expand capability and pipeline. Potential sales angle: pursue co-development or alliance opportunities with cell therapy and vaccine developers seeking external manufacturing capacity and specialized platforms.

University-backed Scale Located within the University of Wisconsin–Madison ecosystem with a cGMP facility opened in 2001 and a history of supporting clinical production, signaling stability and access to academic partnerships and talent. Potential sales angle: leverage proximity to academic spinouts and translational programs for pilot runs, tech transfer, and ongoing collaborations in early-phase development.